MiNK Therapeutics publishes research on CAR-iNKT cell therapy

NEW YORK - MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biotech company with a market capitalization of $161.86 million, announced Tuesday the publication of a peer-reviewed article in Frontiers in Immunology highlighting the potential of CAR-iNKT cells as a next-generation platform for treating solid tumors. The company’s stock has shown remarkable momentum, delivering a 464% return over the past week, according to InvestingPro data.

The article, titled "CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy," details how invariant natural killer T (iNKT) cells may overcome limitations faced by conventional cell therapies in treating solid tumors. While the company’s innovative approach has attracted investor attention, InvestingPro data reveals that MiNK currently operates with negative EBITDA of -$9.78 million, reflecting the early-stage nature of its therapeutic development programs.

MiNK’s lead program, agenT-797, is an unmodified allogeneic iNKT therapy that has shown clinical activity in difficult-to-treat cancers. According to the company, a patient with metastatic testicular cancer achieved complete remission following treatment with agenT-797 combined with anti-PD-1 therapy, with the patient remaining disease-free for more than two years.

The company also reported that in an ongoing Phase 2 trial for second-line gastric cancer, agenT-797 demonstrated immune activation and durable disease control in patients who previously failed immunotherapy.

The published research emphasizes distinctive properties of iNKT cells, including their ability to penetrate tumor microenvironments, lack of alloreactivity allowing for unmatched donor use, and efficacy without requiring lymphodepletion.

MiNK is advancing MiNK-215, an IL-15-armored, FAP-targeting CAR-iNKT cell therapy designed to penetrate fibrotic tumors. Preclinical data suggests this therapy may help overcome resistance to immunotherapy by depleting stromal barriers and promoting T cell infiltration.

"Our allogeneic iNKT platform, agenT-797, has already demonstrated potent, durable activity in solid tumors without lymphodepletion, genetic modification, or complex conditioning," said Jennifer Buell, President and CEO of MiNK Therapeutics, in the press release statement.

The company’s announcement comes as cell therapies continue to face challenges in effectively treating solid tumors, which represent the majority of cancer cases. With its next earnings report scheduled for August 14, 2025, investors seeking deeper insights into MiNK’s financial health and growth prospects can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US equities with expert analysis and actionable intelligence.

In other recent news, MiNK Therapeutics has entered into a $50 million at-the-market sales agreement with B. Riley Securities. This agreement allows MiNK Therapeutics to offer and sell shares of its common stock through B. Riley Securities, as outlined in a registration statement filed with the SEC. Meanwhile, William Blair has downgraded MiNK Therapeutics from Outperform to Market Perform, citing the stock’s significant surge following a publication about a successful cancer treatment case. The publication in Nature’s Oncogene detailed a patient achieving complete remission from metastatic testicular cancer after treatment with MiNK’s iNKT cell therapy, agenT-797, combined with nivolumab.

Additionally, MiNK Therapeutics has announced the publication of another case study in Oncogene, highlighting a patient with metastatic gastric cancer who experienced a 42% tumor reduction after treatment with agenT-797. H.C. Wainwright has maintained a Buy rating on MiNK Therapeutics, with a price target of $35, following these promising results. The company is actively enrolling patients in its ongoing Phase 2 trial in gastric cancer, with more data expected soon. MiNK Therapeutics continues to explore the potential of agenT-797 in treating various conditions, including solid tumors and graft-versus-host disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.